Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and Fcγ receptors

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1446-1451

  Gragnani, Laura ^a   Piluso, Alessia ^a   Giannini, Carlo ^a   Caini, Patrizio ^a   Fognani, Elisa ^a   Monti, Monica ^a   Petrarca, Antonio ^a   Ranieri, Jessica ^a   Razzolini, Giulia ^a   Froio, Valentina ^a   Laffi, Giacomo ^a   Zignego, Anna Linda ^a  

^a Department of Internal Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CRYOGLOBULIN; FC GAMMA RECEPTOR 3A; FC GAMMA RECEPTOR 3B; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION;

EID: 79955562518     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30274     Document Type: Article

References (15)

1. Zignego AL, Giannini C, Ferri C,. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007; 13: 2467-78. (Pubitemid 46929503)
2. Bianchettin G, Bonaccini C, Oliva R, Tramontano A, Cividini A, Casato M, et al. Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. J Virol 2007; 81: 4564-71. (Pubitemid 46668654)
3. Takai T,. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2: 580-92. (Pubitemid 37328733)
4. De Vita S, Quartuccio L, Fabris M,. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both? Autoimmun Rev 2008; 8: 95-9.
5. Cheema GS, Roschke V, Hilbert DM, Stohl W,. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9. (Pubitemid 32537529)
6. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 24: 983-7. (Pubitemid 46638853)
7. Kyogoku C, Dijstelbloem HM, Tsuchiya N, Hatta Y, Kato H, Yamaguchi A, et al. Fcγ receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002; 46: 1242-54. (Pubitemid 34525832)
8. Biezeveld M, Geissler J, Merkus M, Kuipers IM, Ottenkamp J, Kuijpers T,. The involvement of Fcγ receptor gene polymorphisms in Kawasaki disease. Clin Exp Immunol 2007; 147: 106-11. (Pubitemid 44915561)
9. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335-42.
10. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-8. (Pubitemid 34525533)
11. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-9. (Pubitemid 38387177)
12. Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005; 105: 289-91. (Pubitemid 40053095)
13. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007; 125: 30-3. (Pubitemid 47374540)
14. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64: 4664-9. (Pubitemid 38856941)
15. De Re V, Caggiari L, Simula MP, De Vita S, Mazzaro C, Lenzi M, et al. Role of the HLA class II: HCV-related disorders. Ann N Y Acad Sci 2007; 1107: 308-18. (Pubitemid 47528808)